Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.160 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Health Care Company Coherus BioSciences Announces Merger With Surface Oncology ↗

June 16, 2023

Via Benzinga

Coherus BioSciences, MicroVision, Millicom And Other Big Stocks Moving Lower On Friday ↗

June 16, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording losses in today’s session. Coherus BioSciences, Inc. (NASDAQ: CHRS) tumbled 16.8%...

Via Benzinga

US Stocks Mixed; Dow Gains 50 Points ↗

June 16, 2023

U.S. stocks traded mixed this morning, with Dow Jones gaining around 50 points on Friday. Following the market opening Friday, the Dow traded up 0.16% to 34,464.01 while the NASDAQ fell 0.14% to...

Via Benzinga

This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy? ↗

June 16, 2023

Via The Motley Fool

Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M ↗

June 16, 2023

Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that

Via Benzinga

Analyst Expectations for Coherus BioSciences's Future ↗

June 15, 2023

Via Benzinga

Coherus' Toripalimab/Chemo Combo Cuts Death Risk By 37% In Nasopharyngeal Cancer Patients ↗

June 06, 2023

Via Benzinga

Why Is AbbVie Stock Trading Down Today? ↗

June 01, 2023

AbbVie Inc. (NYSE: ABBV) shares are trading lower Thursday after Coherus BioSciences Inc.

Via Benzinga

Coherus to Acquire Surface Oncology

June 16, 2023

From Surface Oncology, Inc.

Via GlobeNewswire

AbbVie vs Coherus: Dispute Emerges over Upcoming Launch of Low-Cost Biosimilar, Yusimry ↗

June 15, 2023

AbbVie Inc (NYSE: ABBV) has challenged Coherus BioSciences Inc (NASDAQ: CHRS), alleging Coherus breached its settlement and license agreement after it announced its plans to launch Yusimry, a...

Via Benzinga

Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma

June 05, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Biotech Alert: Searches Spiking For These Stocks Today - Friday, June 2 ↗

June 02, 2023

Various names in the biotech sector are seeing a substantial increase in search activity today. Such names include the likes of Akebia Therapeautics, Corvus Pharmaceuticals, and Mirati Therapeutics.

Via Talk Markets

Looking Into Coherus BioSciences's Return On Capital Employed ↗

May 23, 2023

Via Benzinga

6 Analysts Have This to Say About Coherus BioSciences ↗

May 23, 2023

Via Benzinga

Coherus BioSciences Earnings Preview ↗

May 05, 2023

Via Benzinga

Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed' ↗

June 01, 2023

One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug...

Via Benzinga

Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients

June 01, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023

June 01, 2023

List price of $995 per carton for two 40 mg/0.8 mL autoinjectors

From Coherus BioSciences, Inc.

Via GlobeNewswire

Top 5 Health Care Stocks That Could Blast Off In May ↗

May 26, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Coherus Announces U.S. Launch of UDENYCA® Autoinjector

May 22, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Friday ↗

May 19, 2023

On Friday, 63 companies hit new 52-week lows.

Via Benzinga

Coherus Prices Public Offering of Common Stock

May 16, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Vodafone, Calliditas Therapeutics, Rumble And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

May 16, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Coherus Announces Proposed Public Offering of Common Stock

May 15, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

Gold Edges Higher; PayPal Shares Tumble Despite Upbeat Earnings ↗

May 09, 2023

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 50 points on Tuesday. The Dow traded down 0.01% to 33,616.00 while the NASDAQ fell 0.43% to...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 09, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 09, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

May 09, 2023

We're starting off the day with the biggest pre-market stock movers traders will want to keep in mind while trading on Tuesday!

Via InvestorPlace

Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 09, 2023

Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease.

Via Benzinga

Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights

May 08, 2023

From Coherus BioSciences, Inc.

Via GlobeNewswire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.